There are two types of association between patients with aplastic anemia (referred to as reblindness) and pregnancy. In one case, aplastic anemia occurs after pregnancy, which may be coincidental, or there may be a particular reason for it; it is not clear whether the occurrence of remittent anemia is associated with pregnancy status. Some patients may spontaneously improve after abortion or delivery, but not all patients have spontaneous remission and often require treatment for remitting disorders. Another situation is that many patients with remittent disease are young women who have a requirement to become pregnant and have children. However, the disease often worsens during pregnancy, and patients with previously effective immunosuppressive therapy are at high risk of relapse during pregnancy. The risk of recurrence of remittent disease is reported in different literature as 19-33%. A normal blood count before pregnancy does not guarantee non-relapse. Relapses during pregnancy in patients with remittent disease can have a significant impact on both the mother and the fetus. The mother may develop secondary eclampsia and even maternal death after delivery has been reported. The fetus may be delivered prematurely, or spontaneously aborted. Blood transfusion support is required during delivery. However, if the delivery is successful, the infant develops normally after delivery. In relapsed patients, the main treatment is blood transfusion support to maintain hemoglobin >80g/l and platelets >20X109/l due to the progress of supportive treatment, especially the availability of blood products, the prognosis has improved greatly compared to decades ago. However, the patient and family should discuss in detail with the treating physician the potentially serious risks to the mother and fetus of continuing the pregnancy. The decision to continue the pregnancy or to terminate the pregnancy should be made carefully after the risks are fully understood. If the decision is made to continue the pregnancy, close follow-up with both the hematologist and the obstetrician is required, and it is important to monitor the patient and the blood picture closely throughout the pregnancy. Monitoring of the patient and the blood picture is important throughout the pregnancy, initially once a month and then more frequently depending on the severity of the disease. The mode of delivery is determined by the obstetric situation.